Swedbank’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Swedbank’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-776,494	Closed	-$89.8M	–	727
2023 Q3	$89.8M	Buy	776,494 +2,300	+0.3%	+$247K	0.16%	118
2023 Q2	$79.6M	Sell	774,194 -316,900	-29%	-$33.4M	0.14%	128
2023 Q1	$119M	Sell	1,091,094 -17,200	-2%	-$1.9M	0.23%	93
2022 Q4	$126M	Sell	1,108,294 -395,300	-26%	-$32.8M	0.28%	81
2022 Q3	$93.1M	Buy	1,503,594 +310,700	+26%	+$21.7M	0.22%	93
2022 Q2	$95.1M	Buy	1,192,894 +534,400	+81%	+$50.6M	0.21%	100
2022 Q1	$69.3M	Buy	658,494 +19,894	+3%	+$1.94M	0.13%	146
2021 Q4	$69.1M	Hold	638,600	–	–	0.12%	155
2021 Q3	$70M	Hold	638,600	–	–	0.13%	149
2021 Q2	$59.8M	Buy	638,600 +20,700	+3%	+$1.9M	0.11%	172
2021 Q1	$56.9M	Buy	+617,900	New	+$52.1M	0.12%	169

Other funds holding HZNP

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

VWA

Valued Wealth Advisors Holladay, Utah $275M AUM 24.94% 1-Year Est. Return

FSWA

Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return

BCMLT

Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Swedbank's HZNP Position: Q4 2023 in Review

Swedbank sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 776,494 shares — an estimated $89.8M sold.

Swedbank first reported a position in HZNP in Q1 2021 and held it in 11 quarters. The position peaked at $126M in Q4 2022. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

Swedbank reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
Swedbank sold 776,494 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $89.8M.
Swedbank first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2021 and held it in 11 quarters.
Swedbank's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $126M in Q4 2022.
6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Swedbank's 13F filing for Q4 2023, filed 6 Dec 2024.